Award
National Cancer Institute 3R01CA285468-03S1
First in Class Small molecules to simultaneously inhibit protein translation and an immune checkpoint in cancers
Recipient
National Cancer Institute (NCI), part of the NIH
Award Amount
$108,736.00
Ceiling
$108,736.00
Awarded
December 11, 2023
Identifier
3R01CA285468-03S1
Award for developing small molecules to inhibit hnRNP A18 for cancer therapy, funded by NIH/NCI, amounting to $108,736 for the period 2023-2028.
Description
The project involves developing small molecules to inhibit hnRNP A18 for cancer therapy. The project is funded by the NIH/NCI for the fiscal year 2026, with a duration from December 11, 2023, to November 30, 2028. The project team includes experts in medicinal chemistry, structural biology, cancer biology, immunology, and oncology.